|
Ovarian Dendritic Cell Vaccine Trial
(Contact: Sandra Zakrzewski, RN, 708-327-2831, SZAKRZE@lumc.edu)
Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma
(Contact: Dr. Steinar Aamdal, steinar.aamdal@medisin.uio.no)
Vaccine Therapy and Chemotherapy With or Without Tretinoin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
(Contact: Clinical Trials Office - H. Lee Moffitt Cancer Center and Resesearch Institute at University of South Florida Recruiting, Tampa, Florida, United States, 33612-9497, 800-456-7121, canceranswers@moffitt.org)
Vaccine Therapy in Treating Patients With Progressive Stage D0 Prostate Cancer
(Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center, 888-NCI-1937)
Trial of Vaccine Therapy in Recurrent Platinum Resistant Ovarian Cancer Patients
(Contact: Dr. Steinar Aamdal, +4722934000, steinar.aamdal@medisin.uio.no)
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
(Contact: Clinical Trials Office - Hoag Cancer Center, 949-764-5543)
Vaccine
Therapy Combined With Interleukin-2
and Interferon alfa in Treating Patients
With Metastatic Renal Cell Carcinoma
(Kidney Cancer) (Contact: Dr. Marc Stuart
Ernstoff, Dartmouth Medical School,
Lebanon, New Hampshire, 03756)
Vaccine
Therapy in Treating Patients With Malignant
Glioma
(Contact: Dr. Linda
M. Liau, UCLA, Los Angeles, CA, 90095)
Vaccine
Therapy in Treating Patients With Liver
Cancer
(Contact: Dr. Antoni
Ribas UCLA, Los Angeles, CA, 90095)
Chemotherapy
Followed By Vaccine Therapy in Treating
Patients With Extensive-Stage Small Cell
Lung Cancer (Contact:
Scott Antonia, H. Lee Moffitt Cancer Center
and Research Institute, Tampa, FL 33612)
Therapy
for Colorectal Cancer
(Contact:
NCI, Bethesda, MD 20892; E-mail: ncicssc@mail.nih.gov)
Study
of Tumor Antigen-Pulsed Autologous Dendritic
Cell Vaccination Administrated Subcutaneously
or Intranodally (Contact:
Mark A Mosby, U. of Arkansas for Medical
Sciences, Little Rock, Arkansas)
A
Safety and Feasibility Study of Active
Immunotherapy in Patients with Metastatic
Prostate Carcinoma Using Autologous Dendritic
Cells Pulsed with Antigen Encoded in Amplified
Autologous Tumor RNA
(Contact: Doris M.
Coleman, Duke University Medical Center,
Durham, North Carolina)
PROvenge
Trial
(Multiple sites throughout
the US) for early stage prostate cancer
patients who have undergone a radical
prostatectomy and whose only sign of disease
recurrence is a rise in serum PSA.
Tumor
Lysate Pulsed-Dendritic Cell Vaccines
after High-Dose Chemotherapy for Non-Hodgkin's
Lymphoma
Vaccine
Therapy With Either Neoadjuvant or Adjuvant
Chemotherapy and Adjuvant Radiation Therapy
in Treating Women With p53-Overexpressing
Stage II or Stage III Breast Cancer (Contact: Dr. Elizabeth
Reed, Eppley Cancer Center at the University
of Nebraska Medical Center, Omaha, Nebraska,
68198)
Vaccine
Therapy in Treating Patients With Advanced
or Metastatic Cancer expressing CEA (Contact: Herbert
Kim Lyerly Duke Comprehensive Cancer Center,
Durham, NC)
Vaccine
Therapy in Treating HLA-A201 Positive
Patients With Refractory CEA Expressing
Stage IV Cancer (Contact: Herbert Kim Lyerly Duke Comprehensive Cancer Center, Durham, NC)
Vaccine
Therapy in Treating Patients With Stage
III or Stage IV Melanoma
(contact: Gerold Schuler,
Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum
Erlangen, Erlangen, D-91052, Germany)
|
